Solventum (NYSE:SOLV) Downgraded to “Neutral” Rating by UBS Group

Solventum (NYSE:SOLV) was downgraded by analysts at UBS Group from a “buy” rating to a “neutral” rating in a report issued on Thursday, Marketbeat Ratings reports. They currently have a $50.00 price objective on the stock. UBS Group’s price target points to a potential downside of 32.82% from the stock’s current price.

SOLV has been the topic of several other reports. Piper Sandler decreased their price target on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Weiss Ratings reissued a “hold (c)” rating on shares of Solventum in a report on Tuesday, January 27th. Stifel Nicolaus decreased their target price on shares of Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Wall Street Zen cut shares of Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Finally, Rothschild & Co Redburn initiated coverage on shares of Solventum in a research report on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price target for the company. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $83.36.

Solventum Trading Down 0.9%

Shares of NYSE:SOLV opened at $74.43 on Thursday. Solventum has a 12-month low of $62.38 and a 12-month high of $88.20. The business has a 50 day moving average of $67.79 and a 200-day moving average of $74.55. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. The stock has a market cap of $12.89 billion, a PE ratio of 9.12, a P/E/G ratio of 1.16 and a beta of 0.59.

Solventum (NYSE:SOLV) last announced its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. The company had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, equities research analysts forecast that Solventum will post 6.58 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Amy Mcbride Wendell bought 1,475 shares of the company’s stock in a transaction dated Tuesday, March 10th. The stock was bought at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the transaction, the director owned 5,039 shares of the company’s stock, valued at $342,803.17. This represents a 41.39% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.24% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Solventum

A number of large investors have recently modified their holdings of the business. Sei Investments Co. raised its holdings in shares of Solventum by 335.0% during the 1st quarter. Sei Investments Co. now owns 240,581 shares of the company’s stock worth $15,711,000 after buying an additional 185,271 shares in the last quarter. Lido Advisors LLC grew its position in Solventum by 13.0% in the first quarter. Lido Advisors LLC now owns 8,922 shares of the company’s stock valued at $583,000 after acquiring an additional 1,023 shares during the last quarter. State of Wyoming grew its position in Solventum by 768.1% in the first quarter. State of Wyoming now owns 6,363 shares of the company’s stock valued at $416,000 after acquiring an additional 5,630 shares during the last quarter. Cetera Investment Advisers raised its stake in Solventum by 5.0% during the first quarter. Cetera Investment Advisers now owns 45,739 shares of the company’s stock worth $2,987,000 after acquiring an additional 2,166 shares in the last quarter. Finally, First Trust Advisors LP raised its stake in Solventum by 57.4% during the first quarter. First Trust Advisors LP now owns 334,441 shares of the company’s stock worth $21,839,000 after acquiring an additional 121,989 shares in the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.